The future of inhaled medications and inhalation technology: formulations, devices and strategy through non-clinical development

Written by Simon Moore, Director of Inhalation Science and Engineering at Envigo
General interest


Summary

Historically, inhaled drugs have been used to deliver medicines targeted at the main respiratory diseases, namely asthma and chronic obstructive pulmonary disease (COPD). The need for efficacious medications for these incurable diseases is still a major focus for research, and off-patent drugs are able to bring in large revenues. Innovations in drug formulation engineering techniques and inhalation device designs are leading to more efficacious new, combination and generic drugs.

This White Paper Includes:

  • The current trends in inhalation technology
  • The industry’s first-to-market trend setters
  • The potential of new particle engineering techniques to lower doses and increase drug efficacy
  • The impact of inhalation technology strategy on drug discovery and non-clinical development

Click here to view the White Paper

Click here for more information on Envigo